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Abstract
Backgrounds: Diabetes is one of the most common metabolic disorders worldwide. This study aim was to provide
detail analysis of diabetes research output and its trend in Iran as well as in the world and compare them.
Methods: Data was retrieved from PubMed database using a suitable search strategy and application of proper operator
“AND”, “OR” and “NOT”. All English documents published from 2008 to 2012 were included. Meeting abstract, letter to the
editor, guidelines, consensus and reviews were excluded. Obtained documents for Iran and world were categorized in
eleven groups including diabetes management, education, paediatrics, nutrition, epidemiology, diabetes complications,
stem cells, gestational diabetes mellitus (GDM), psychiatrics, genetics and prevention and were compared.
Results: Total number of DM publications was 59513 for world and 648 for Iran. Trend of DM publications
was increasing during the 5 years with a growth rate of 22.5% for world and 23.4% for Iran. Contribution of
Iran in the world diabetes output reached 1.08 in 2012. The most and the least number of DM documents
were related to complications and preventions, respectively both in Iran and the world. Three leading
countries with highest proportion of RCTs (randomized clinical trial) to their total DM publications were Italy,
Germany and Iran.
Conclusion: The most number of diabetes research was in the field of diabetes complication, management
and genetics in the world as well as in Iran. During the 5-year period, despite of the world sanctions against
Iran, diabetes research trend was increasing in Iran relatively parallel to the world research and sanction had
no significant effect on Iran.
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Background
Diabetes, one of the most common non-communicable
diseases (NCDs), is the fourth or fifth leading cause of
death in most high-income countries and is certainly one
of the biggest health challenges facing the world today [1].
Diabetes prevalence has dramatically increased in many
countries over the past decades. According to IDF reports,
415 million people are estimated to have diabetes in 2015
which will rise to 642 million by 2040 [2].
Amongst all regions, the Middle East and North Africa
Region (MENA), where Islamic Republic of Iran is
belonged to, has the highest prevalence of people with
diabetes. According to the latest estimates, 35.4 million
people, or 9.1% of the adult population, have diabetes in
MENA and this number is expected almost double by
2035 [2, 3].
Surprisingly, Iran owns the third place in terms of the
total number of adult population with diabetes across
the MENA region (4,602.2 adults with diabetes (20–79)
in 1000 s) [2].
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Diabetes imposes a large economic burden on national
health care systems worldwide and so more prevention and
management efforts are required to relieve this burden [4].
Health spending on diabetes accounted for 11.6% of
total health expenditure worldwide in 2015. With such a
high cost burden, the disease is an obstacle to sustain-
able economic development [2, 5].
In Iran, also, diabetes consumes more than 8.6% of
total health expenditure. Diabetic patients have four
times higher rates of hospitalization [6], 2.6 times
higher numbers of annual physician visits and 2.5
times greater volume of drug prescriptions than non-
diabetic patients [7, 8].
Today, although there is no cure for this progressive
disease, new drugs and a holistic approach to treatment
have improved prognosis and quality of life, morbidity
and mortality due to diabetes complications. On the
other hand, the grand challenge of curing diabetes will
only be met through increased research and so obvious
that success depends not only on increased funding, but
also on more rational use of research budgets and better
coordination [9]. The United States has been successful
in this context with the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK) oversee-
ing, coordinating and funding the federal diabetes re-
search effort in a most effective fashion. In Europe,
also the Research Directorate of the European Com-
mission has developed a road map for diabetes
research (DIAMAP) in collaboration with Alliance for
European Diabetes Research (EURADIA), a non-profit
organization with the mission to promote diabetes re-
search in Europe [10, 11].
However, there is no a similar organization or institute
in Iran with aims to supervise our research, and possibly
resulting in precious research funds not being invested
as effectively as they might.
The current approach to research we have today in
Iran, with mostly random and uncoordinated invest-
ment, lags behind the international competitiveness of
Iranian research [12, 13]. In this regards, this preliminary
study was conducted to obtain an overview about dia-
betes research in the world and Iran, before developing a
roadmap for diabetes research called “Iran Diabetes Re-
search Roadmap (IDRR) study” to recognize the chal-
lenges, gaps and opportunities in diabetes research in
Iran. With such research road maps in mind, IDRR
study seeks to ensure that diabetes research priorities
can engage with both national plans and with larger-
scale more general strategic approaches to funding and
coordination.
This study is a bibliometric study aimed to analyse a
body of literature and report characteristics of diabetes
research output and its trend in Iran and world and
compare them.
Materials and methods
“Iranian Diabetes Research RoadMap” project has been
coordinated by Iranian Diabetes Research Network
(IDRN) and overseen by a Project Steering Committee
(PSC) which provided scientific guidance to the project.
Iranian Diabetes Research Network was first established
in 2002 by Endocrinology and Metabolism Research In-
stitute (EMRI) at Tehran University of Medical Sciences
in collaboration with Ministry of Health and Medical
Education with the primary goals of expanding know-
ledge and reforming practice in all aspects of diabetes
care, facilitating the translation of evidence-based know-
ledge into practice through active cooperation between
the network members, organizing diabetes care pro-
grams for the general populations, patients and health
care providers and finally conducting research projects
in the field of diabetes.
To obtain and compare scientific production of the
world and Iran about diabetes during a 5-year period
(2008–2012) a comprehensive search was done in
PubMed database using the first search strategy.
“First Search Strategy” was used to acquire results re-
lated to diabetes in the world. In this stage, PubMed
search was done by using the following MeSH Terms:
“Diabetes Mellitus” [Mesh] OR “Diabetes Mellitus, Type
1” [Mesh] OR “Diabetes Mellitus, Type 2” [Mesh]. To
retrieve diabetes articles in lran, another search was
done on PubMed database using the following keywords:
“Diabetes Mellitus” [Mesh] OR “Diabetes Mellitus, Type
1” [Mesh] OR “Diabetes Mellitus, Type 2” [Mesh] AND
(Iran [MeSH] OR Iranian OR Iranians OR I.R. Iran).
This search strategy was considered as the “Second
Search Strategy”.
All search results were limited to the years 2008–2012
and duplicate documents, meeting abstract, letter to the
editor, guidelines, consensus and reviews were excluded.
Also, only English documents were eligible. All docu-
ments related to Iran were removed from the world
search results.
Following the first search protocol, 73299 records were
obtained. Then after excluding unrelated documents ac-
cording to the title (11459) a total number of 61840 arti-
cles remained. These records were evaluated based on
the abstract and texts and finally 59513 documents
remained that were categorised (2327 were unrelated
and excluded after second screen).
The second search strategy, for retrieving Iranian
publications, resulted in 723 records. In first scre-
ening, after excluding duplications and unrelated
documents based on the title, 692 records remained
(31 records removed). In the second screening based
on the abstract and text of articles, 44 documents
were unrelated and excluded and finally 648 docu-
ments remained.
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Then results of each group (world and Iran) were cate-
gorized separately in eleven categories according to their
titles, abstracts or full texts by the working groups. Stud-
ies irrelevant to all eleven research areas or unrelated
studies were removed. Articles on more than one area
where put in two or more categories.
Obtained diabetes documents were categorized in













Each working group was supervised by an expert with
comprehensive scientific knowledge in the relevant area
and more broadly in diabetes research.
In addition, top five countries in diabetes research
were identified by transferring the primary results of the
first search strategy to RefViz software and then ranked
based on the corresponding authors’ country.
Since Randomized Control Trials are of high value in
comparison to other types of studies, we retrieved RCTs
(randomized clinical trial) by filtering the first and sec-
ond search results to “RCT” and identified the total
number of RCTs both in Iran and the world over the
years 2008–2012. Moreover, five leading countries in
conducting RCTs in the field of diabetes were also iden-
tified using RefViz software based on the corresponding
authors’ country.
To evaluate annual research growth rate and compare
this rate between Iran and the world a comprehensive
analysis method was required. For this purpose, numbers
of published papers were transformed to proportions for
further analysis. For each year of study, the proportions
of annual publications of each research area were calcu-
lated by dividing the number of published papers to the
total number of publications in all 11 categories during
5 years. These proportions were tested for temporal
trends during 5 years by Cochran-Armitage trend test
(using function prop.trend.test in R). The correlations of
these quantities between Iran and the world were
assessed; also we measured these correlations with one-
year lag. Considering diabetic RCTs publications, the
equality of proportions of all RCTs to total diabetic pub-
lications for 5 years were tested by chi-square test, also
the annual proportion of RCTs to total diabetic publica-
tions were calculated for each country. Pairwise correl-
ation was calculated between each two countries. In
order to find likely clusters of countries according to the
proportion of RCTs publications, we implied cluster ana-
lysis through hierarchical clustering method, Using
hclustvar function in R package ClustOfVar**. All ana-
lyses were conducted using R: 2.15.2.
Results
During the study period (5 years), number of total DM
publications was 59513 for world and 648 for Iran. Total
world DM publications increased from 10519 in 2008 to
13567 in 2012 with a change rate of 22.5% during this
period while contribution of Iranian publications to the
world total DM publications was 0.93% in 2008 and
reached 1.08% in 2012 with a change rate of 23.4%
(Fig. 1).
Table 1 demonstrates the number and proportion of
publications in each field of study for world and Iran.
These eleven fields constitute about 70% of total world-
wide DM publications and 86.1% of total Iranian DM
publications. Complications and preventions had the
most and the least proportions of the total DM publica-
tions during 5 years, respectively both in Iran and the
world (Table 1).
Figure 2 demonstrates annual trends of the number of
publication of each field to the total DM publications in
Iran. Complications had consistently the most yearly
contribution of total DM publications. Although the an-
nual contribution of GDM, genetics, educations,
pediatrics, nutrition, management, and psychiatrics to
the total Iranian publications was increasing from 2008,
but unique trend was not observed in these fields.
The impact of each field over the period of study is
presented in Fig. 3. There was an increasing trend (p <
0.05 for trend) in the number of worldwide publications
Fig. 1 Contribution of Iranian Total DM Publications to the World Total
DM Publications
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in each field of research, except prevention (p = 0.775 for
trend) that shows fluctuation. Iran showed increasing
trend with constant rates for the number of publications
of complications (p = 0.005 for trend) and management
(p = 0.002 for trend). Also an increasing trend was ob-
served in the number of publications of genetics (p =
0.032), educations (p = 0.020), nutrition (p = 0.001), and
psychiatrics (p = 0.004).
World RCTs constituted 11.4% of total world diabetes
publications during these 5 years. Contribution of RCT
publications of each country to the total number of
world RCT publications are represented in Table 2.
While the USA was leading among leading countries,
Iran had the least contribution to the total number of
RCTs (28.5% vs.1.29%). Also the proportion of RCTs of
each country to its total DM publications is represented
in Table 2. Italy had the most contribution of diabetic
RCTs publications to its total diabetic publications
(15.8%), and China had the least one (6.5%), this propor-
tion was 15.4% for Germany. Iran was in the third place
of having high contribution of RCTs to total diabetic
publications (14.2%). We probed into Iran and other six
leading countries’ proportion of diabetic RCTs to total
Diabetic articles (Table 2).
The annual proportion of world RCTs to the world
total diabetes articles was 11.7, 11.6, 10.3, 11.9 and
11.3%, respectively from 2008 to 2012. There was no sig-
nificant trend in proportion of annual RCT publications
to the total DM publications during 2008 to 2012 (p =
0.757 for trend).
From dendrogram, as a result of cluster analysis, in
Fig. 4, we concluded that there were two major clusters.
The first cluster consisted of the Germany, China, UK,
and Italy in which Germany and China clustered to-
gether at the distance of 0.05, and then UK merged to
this group at the distance of 0.23 and Italy added to this
cluster at the distance of 0.7. The second cluster consists
of the USA, Japan, and Iran. Japan and the USA merged
together at the minimum distance of 0.3, this group
Table 1 Field Contribution to the total DM Research of World
and Iran during 5 years
World Iran
Field of Study Number of DM
Publications
Percent Number of DM
Publications
Percent
Complications 13598 22.9 198 30.6
Management 6617 11.1 77 11.9
Genetics 4980 8.4 72 11.1
Epidemiology 3675 6.2 38 5.9
Pediatrics 2882 4.8 21 3.2
Nutrition 2171 3.7 53 8.2
GDM 1917 3.2 37 5.7
Education 1368 2.3 14 2.2
Stem Cells 1109 1.9 15 2.3
Psychiatrics 604 1.01 27 4.2
Prevention 470 0.79 6 0.9
Fig. 2 Proportion that each field accounts for in the total number of DM Publications for each year in Iran (P-value of trend test is represented
for each field)
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differed from Iran with a distance of 0.6 and these three
countries formed a new cluster. The distance between
the two major clusters was 1.4.
As we can see in Fig. 5, there was a uniform pattern
for the proportion of diabetic RCTs to all diabetes publi-
cations for leading countries (p > 0.05 for trend, results
are not shown), an exception observed for UK which
had a decreasing pattern (p = 0.023 for trend) but Iran
showed an increasing trend during these 5 years (p =
0.025 for trend).
Discussion
This study showed increasing trend of Iran and world
DM publications during the study period (2008–2012).
Iranian researchers in this period published 648 articles
about diabetes while at the same time 59513 articles
about DM was published in the world. Proportion of
RCTs to other diabetes research in Iran (14.1%) was
higher than US and UK (11.8 and 12.5%, respectively).
Italy and Germany had highest proportion of RCTs
compared to other countries (15.87 and 15.37%,
respectively).
The first bibliometric study about diabetes research
output in Iran was conducted by Rezaei et al. In that
study, the number of DM publications by Iranian
authors increased from zero to 9 from 1992 to 2002 and
Iran publications trend had the highest growth rate
among Middle East countries. Contribution of Iran in
the world DM scientific production in that time was
only 0.2% and Iran took the fourth place after Saudi
Arabia, Kuwait and Egypt among Eastern Mediterranean
region countries [14].
In Rasolabadi et al., recent study about world dia-
betes research output, Iran cumulative DM publica-
tions until the end of 2014 was 4425 documents and
annual growth rate of Iran scientific production in
DM was 25.5% during the same period. However, this
growth rate was negative and decreased to 14.16% be-
tween the years 2013 and 2014. These findings are
similar to ours [15].
Fig. 3 Proportion that each field accounts for in the total number of publications of each field (dashed line: worldwide publications, solid line:
Iranian publications)
Table 2 Proportion of each country RCTs to total world RCT
articles and to the country total DM publications












aTotal DM publications of each country during years of 2008–2012
bTotal world RCTs during years of 2008-2012
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Also, in that study among the top 25 world countries,
Iran with a global share of 0.7% took 25th place in pro-
duction of the world diabetes knowledge [15]. In our
study contribution of Iran in the world diabetes know-
ledge production with a growth rate of 23.4% was 1.08%
during 5 years of study (from 2008 to 2012) which is
higher than the world global growth rate (22.5%).
According to Peykari et al study, between 1990 and
2012, three countries of Turkey (30.2%), Israel
(27.4%), and Iran (12.7%), respectively were the first
three leading countries in the region that produced
about 70% of DM knowledge in the region. The over-
all growth rate of Iran publications was 9% in the
same period [16]. In our study, about 10 years after
the first report [14], Iran contribution in the world
DM output only increased 0.88% compared to the
first report and reached to 1.08% and took third place
in the region [16]. However, as the duration of
Rasolabadi et al study was longer than ours, global
share of Iran was reported 0.7% in that study from
the beginning until the end of 2014 [15]. Contribu-
tion of Iran in diabetes output production in the
Middle East region was reported 12.7% by Peykari et
al in a 22-year period from 1990 to 2012 [16].
Also, citation of Iran diabetes publications increased
during the study period and reached the highest number
in 2014. Average citation per paper in that study was re-
ported 10.4 in 2014 which is higher than prior years [15].
Geaney et al. in their recent study evaluated world dia-
betes research output and found that the greatest number
of documents were published in 2010 and United States
had the greatest contribution in overall output (28.8%)
followed by United Kingdom (8.2%) and Japan (7.58%)
[17]. The same results was reported by Rasolabadi et al
study in Iran [15].
Also, in another study Indian diabetes research out-
puts were analyzed. That study evaluated India publi-
cation trend between 1999 and 2008 and reported an
annual average growth rate of 13.7% [18]. Gupta
et al., classified diabetes research output under seven
broad subject areas and showed that medicine,
followed by biochemistry, genetics and molecular biol-
ogy (28.6%), pharmacology, toxicology, and pharma-
ceutics (22.9%), agricultural and biological sciences
(7.4%), chemistry (6%), neurosciences (2.9%) and im-
munology and microbiology (2.5%), respectively were
the most common subject of these studies [18]. In
their study, from 1999 to 2008, United States, Britain
and Japan, respectively were the first three countries
with the highest contribution in the world diabetes
scientific output [18]. In Geaney et al study in 2012
again the same countries were three leading countries
in the world scientific production about diabetes [17].
Fig. 4 Dendrogram of Countries According to Their Proportion of Publications
Fig. 5 Annual proportion of RCTs to its total DM publications for
leading countries
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Our study showed that diabetes research field in Iran
was relatively comparable to the world and the highest
number of diabetes field production was related to dia-
betes complication followed by management and genetics.
However, the ratio of Iran scientific production in the field
of diabetes complications, nutrition, genetics and psych-
iatry to its total diabetes scientific production was higher
than the same ratio of the world in the same period.
Although diabetes research in Iran is to somewhat in
line of the world, but it is time to move from quantity to
quality and more focus on production of high quality
documents with higher level of evidence (level A and B)
such as RCTs, systematic review and meta-analysis as
well as evaluation of interventions, HSRs (Health System
Research) and cost analysis study. More attempts should
be made to increase the quality of RCTs to be used in
our future diabetes guideline [13].
Future studies with a comprehensive search strategy is
required to evaluate research output in different fields
related to diabetes (such as management, complication,
nutrition…) in Iran and compare with the world and fol-
low their trend in the next years.
Conclusion
In conclusion, it seems that despite of the world sanc-
tions against Iran and limited access to the resources
during the study period, diabetes research has not been
affected in Iran [12] and it is growing relatively parallel
to the world research with few limitations. The trend of
Iranian diabetes output was increasing during the 5-year
period (2008–2012) although it was not equal and con-
stant in different subject fields of diabetes in all years. It is
predicted to have more and better collaboration with the
world and considerable improvement in the quality and
number of diabetes research production after removing
world sanctions and progression of BARJAM (Iran nuclear
deal with world powers) execution after 2015.
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